InvestorsHub Logo
Followers 2
Posts 2974
Boards Moderated 0
Alias Born 06/23/2017

Re: None

Wednesday, 03/28/2018 10:49:19 PM

Wednesday, March 28, 2018 10:49:19 PM

Post# of 44784
Have a look at the "about Pluristem" section from 2007 when Carlucci joined. Ten years later they started phase 1. Now THAT'S great leadership. Direction...focus...goals... A direct result of the "learn as you go" motto. But they got this now!!! All is well!!! All is well!!!

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).